Longeveron's ELPIS II trial misses primary endpoint in HLHS study
The Phase 2b trial of laromestrocel failed to improve right ventricular ejection fraction, and Longeveron said it will review all options to maximize shareholder value.
SEC filing
Latest
4 stories
Wednesday, September 23
Wednesday, August 19
Longeveron names Nirav Jhaveri as chief financial officer
The clinical-stage biotech said Jhaveri succeeds Marie Washburn, who returns to her prior role as corporate controller, effective August 17, 2026.
SEC filing
Wednesday, August 12
Longeveron reports Q2 2026 results, keeps September readout for HLHS heart trial
Longeveron said its Phase 2b HLHS trial for laromestrocel remains on track for September top-line data, with cash on hand extending only into the fourth quarter of 2026.
SEC filing
Tuesday, July 14
Longeveron names Marie Washburn as CFO, revises CEO pay, grants Executive Chairman equity
Three July 2026 filings detail Longeveron's finance leadership change, an amended CEO letter agreement, and special equity awards for its Executive Chairman.
SEC filing (3)